Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Not Interested In Acquisitions for Scale, Flat Revenues But Growing Margins

This article was originally published in The Pink Sheet Daily

Executive Summary

Little to say on Brilinta, sales momentum driven by Symbicort, Seroquel and Crestor.

You may also be interested in...



Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely

Sanofi-Aventis is interested in acquiring a company with market cap up to $20 billion, CEO Viehbacher says, leaving open the possibility of acquiring Genzyme.

Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results

FDA's Cardiovascular and Renal Drugs Advisory Committee votes 7-1 in favor of ticagrelor's approval for acute coronary syndromes despite rejecting AstraZeneca's aspirin-dosing theory as the sole cause of lack of benefit in the U.S. population.

Crestor Label Lends Validity To Controversial C-Reactive Protein Test

FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel